Liposomes in topical photodynamic therapy

Expert Opinion on Drug Delivery

Volumn 9, Issue 8, 2012, Pages 1015-1032

  Dragicevic Curic, Nina ^a   Fahr, Alfred ^b  

^a Apoteka Beograd   (Serbia)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

5 aminolevulinic acid; Liposome; Temoporfin; Topical photodynamic therapy; Vesicle

Indexed keywords

AMINOLEVULINIC ACID; AMINOLEVULINIC ACID METHYL ESTER; BLUE U; DRUG CARRIER; LIPOSOME; METHYLENE BLUE; PHOTOSENSITIZING AGENT; TEMOPORFIN; UNCLASSIFIED DRUG;

CYTOTOXICITY; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PENETRATION; DRUG STRUCTURE; ENCAPSULATION; HUMAN; NONHUMAN; PHOTODYNAMIC THERAPY; REVIEW; SKIN DEFECT; SKIN PENETRATION;

AMINOLEVULINIC ACID; DRUG CARRIERS; HUMANS; LIGHT; LIPOSOMES; MESOPORPHYRINS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; SKIN DISEASES;

EID: 84864262917     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2012.697894     Document Type: Review

References (141)

1. Dougherty TJ, Gomer CJ, Henderson BW, et al. Photodynamic therapy. J Natl Cancer Inst 1998;90:889-905
2. Hopper C. Photodynamic therapy: A clinical reality in the treatment of cancer. Lancet Oncol 2000;1:212-19
3. Biel MA. Photodynamic therapy in head and neck cancer. Curr Oncol Rep 2002;4:87-96
4. Kubler AC, Haase T, Staff C. Photodynamic therapy of primary non-melanomatous skin tumours of the head and neck. Laser Surg Med 1999;25:60-8
5. Lien MH, Sondak VK. Nonsurgical treatment options for Basal cell carcinoma. J Skin Cancer 2011;2011:5717-34
6. Morton CA, McKenna KE, Rhodes LE; British Association of Dermatologists Therapy Guidelines and Audit Subcommittee and the British Photodermatology Group. Guidelines for topical photodynamic therapy: update. Br J Dermatol 2008;159:1245-66
7. Peng Q, Soler AM, Warloe T, et al. Selective distribution of porphyrins in skin thick basal cell carcinoma after topical application of methyl 5-aminolevulinate. Photochem Photobiol B 2001;62:140-5
8. Ahmadi S, McCarron PA, Donnelly RF, et al. Evaluation of the penetration of 5-aminolevulinic acid through basal cell carcinoma: A pilot study. Exp Dermatol 2004;13:445-51
9. Rhodes LE, de Rie M, Enstrom Y, et al. Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma: Results of a multicenter randomized prospective trial. Arch Dermatol 2004;140:17-23
10. Mosterd K, Thissen MR, Nelemans P, et al. Fractionated 5-aminolaevulinic acid-photodynamic therapy vs. surgical excision in the treatment of nodular basal cell carcinoma: Results of a randomized controlled trial. Br J Dermatol 2008;159:864-70
11. Barry BW. Breaching the skin's barrier to drugs. Nat Biotechnol 2004;22:165-7
12. Benson HA. Transdermal drug delivery: Penetration enhancement techniques. Curr Drug Deliv 2005;2:23-33
13. Rizwan M, Aqil M, Talegaonkar S, et al. Enhanced transdermal drug delivery techniques: An extensive review of patents. Recent Pat Drug Deliv Formul 2009;3:105-24
14. El Maghraby GM, Williams AC, Barry BW. Skin delivery of 5-fluorouracil from ultradeformable and standard liposomes in vitro. J Pharm Pharmacol 2001;53:1069-77
15. Yuan JS, Yip A, Nguyen N, et al. Effect of surfactant concentration on transdermal lidocaine delivery with linker microemulsions. Int J Pharm 2010;392:274-84
16. Pardeike J, Hommoss A, Muller RH. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm 2009;366:170-84
17. Lopez RF, Bentley MV, Begona Delgado-Charro M, Guy RH. Optimization of aminolevulinic acid delivery by iontophoresis. J Control Release 2003;88:65-70
18. Cancel LM, Tarbell JM, Ben-Jebria A. Fluorescein permeability and electrical resistance of human skin during low frequency ultrasound application. J Pharm Pharmacol 2004;56:1109-18
19. Rastogi R, Anand S, Koul V. Electroporation of polymeric nanoparticles: An alternative technique for transdermal delivery of insulin. Drug Dev Ind Pharm 2010;36:1303-11
20. Bachhav YG, Heinrich A, Kalia YN. Using laser microporation to improve transdermal delivery of diclofenac: Increasing bioavailability and the range of therapeutic applications. Eur J Pharm Biopharm 2011;78:408-14
21. Christensen E, Mørk C, Foss OA. Pre-treatment deep curettage can significantly reduce tumour thickness in thick Basal cell carcinoma while maintaining a favourable cosmetic outcome when used in combination with topical photodynamic therapy. J Skin Cancer 2011;2011:240340
22. Basset-Seguin N, Ibbotson SH, Emtestam L, et al. Topical methyl aminolaevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: A 5 year randomized trial. Eur J Dermatol 2008;18:547-53
23. Ibbotson SH. Topical 5-aminolaevulinic acid photodynamic therapy for the treatment of skin conditions other than non-melanoma skin cancer. Br J Dermatol 2002;146:178-88
24. De Rosa FS, Bentley MV. Photodynamic therapy of skin cancers: Sensitizers, clinical studies and future directives. Pharm Res 2000;17(12):1447-55
25. Choi MJ, Maibach HI. Liposomes and niosomes as topical drug delivery systems. Skin Pharmacol Physiol 2005;18:209-19
26. El Maghraby GM, Williams AC. Vesicular systems for delivering conventional small organic molecules and larger macromolecules to and through human skin. Expert Opin Drug Deliv 2005;6:149-63
27. De Leeuw J, De Vijlder HC, Bjerring P, Neumann HA. Liposomes in dermatology today. J Eur Acad Dermatol Venereol 2009;23(5):505-16
28. Derycke ASL, De Witte PAM. Liposomes for photodynamic therapy. Adv Drug Deliv Rev 2004;56:17-30
29. Verma DD, Verma S, Blume G, Fahr A. Liposomes increase skin penetration of entrapped and non-entrapped hydrophilic substances into human skin: A skin penetration and confocal laser scanning microscopy study. Eur J Pharm Biopharm 2003;55:271-7
30. Seth AK, Misra A, Umrigar D. Topical liposomal gel of idoxuridine for the treatment of herpes simplex: Pharmaceutical and clinical implications. Pharm Dev Technol 2004;9:277-89
31. Schmid MH, Korting HC. Therapeutic progress with topical liposome drugs for skin disease. Adv Drug Deliv Rev 1996;18:335-42
32. Kirjavainen M, Urti A, Jaaskelainen L, et al. Interaction of liposomes with human skin in vitro-the influence of lipid composition and structure, Biochim. Biophys Acta 1996;1304:179-89
33. Van Kuijk-Meuwissen MEMJ, Junginger HE, Bouwstra JA. Interactions between liposomes and human skin in vitro, confocal laser scanning microscopy study. Biochim Biophys Acta 1998;1371:31-9
34. Van den Bergh BAI, Vroom J, Gerritsen H, et al. Interactions of elastic and rigid vesicles with human skin in vitro: Electron microscopy and two-photon excitation microscopy. Biochim Biophys Acta 1999;1461:155-73
35. Honeywell-Nguyen PL, De Graaff AM, Wouter Groenink HW, Bouwstra JA. The in vivo and in vitro interactions of elastic and rigid vesicles with human skin. Biochim Biophys Acta 2002;1573:130-40
36. Cevc G, Blume G. Biological activity and characteristics of triamcinolone-acetonide formulated with the self-regulating drug carriers, Transfersomes. Biochim Biophys Acta 2003;1614:156-64
37. Srisuk P, Thongnopnua P, Raktanonchai U, Kanokpanont S. Physico-chemical characteristics of methotrexate-entrapped oleic acid-containing deformable liposomes for in vitro transepidermal delivery targeting psoriasis treatment. Int J Pharm 2012;427(2):426-34
38. Cevc G, Mazgareanu S, Rother M, Vierl U. Occlusion effect on transcutaneous NSAID delivery from conventional and carrier-based formulations. Int J Pharm 2008;359:190-7
39. Celia C, Cilurzo F, Trapasso E, et al. Ethosomes® and Transfersomes® containing linoleic acid: Physicochemical and technological features of topical drug delivery carriers for the potential treatment of melasma disorders. Biomed Microdevices 2012;14:119-30
40. Touitou E, Dayan N, Bergelson L, et al. Ethosomes-novel vesicular carriers: Characterization and delivery properties. J Control Release 2000;65:403-18
41. Wo Y, Zhang Z, Zhang Y, et al. Preparation of ethosomes and deformable liposomes encapsulated with 5-fluorouracil and their investigation of permeability and retention in hypertrophic scar. J Nanosci Nanotechnol 2011;11:7840-7
42. Dragicevic-Curic N, Scheglmann D, Albrecht V, Fahr A. Temoporfin-loaded invasomes: Development, characterization and in vitro skin penetration studies. J Control Release 2008;127:59-69
43. Dragicevic-Curic N, Scheglmann D, Albrecht V, Fahr A. Development of different temoporfin-loaded invasomesnovel nanocarriers of temoporfin: Characterization, stability and in vitro skin penetration studies. Colloids Surf B Biointerfaces 2009;70:198-206
44. Chen M, Liu X, Fahr A. Skin penetration and deposition of carboxyfluorescein and temoporfin from different lipid vesicular systems: In vitro study with finite and infinite dosage application. Int J Pharm 2011;408:223-34
45. Mura S, Manconi M, Valenti D, et al. Transcutol containing vesicles for topical delivery of minoxidil. J Drug Target 2011;19:189-96
46. Cevc G, Blume G. New, highly efficient formulation of diclofenac for the topical, transdermal administration in ultradeformable drug carriers. Transfersomes. Biochim Biophys Acta 2001;1514:191-205
47. Schatzlein A, Cevc G. Non-uniform cellular packing of the stratum corneum and permeability barrier function of intact skin: A high-resolution confocal laser scanning microscopy study using highly deformable vesicles (Transfersomes). Br J Dermatol 1998;138:583-92
48. Dijkstra AT, Majoie IM, van Dongen JW, et al. Photodynamic therapy with violet light and topical 6-aminolaevulinic acid in the treatment of actinic keratosis, Bowen's disease and basal cell carcinoma. J Eur Acad Dermatol Venereol 2001;15:550-4
49. Jeffes EW, McCullough JL, Weinstein GD, et al. Photodynamic therapy of actinic keratoses with topical aminolevulinic acid hydrochloride and fluorescent blue light. J Am Acad Dermatol 2001;45:96-104
50. Jeffes EW. Levulan: The first approved topical photosensitizer for the treatment of actinic keratosis. J Dermatolog Treat 2002;13(Suppl 1):S19-23
51. Gold MH, Nestor MS. Current treatments of actinic keratosis. J Drugs Dermatol 2006;5(Suppl 2):S17-25
52. Morton CA, Whitehurst C, Moore JV, MacKie RM. Comparison of red and green light in the treatment of Bowen's disease by photodynamic therapy. Br J Dermatol 2000;143:767-72
53. Fritsch C, Ruzicka T. Fluorescence diagnosis and photodynamic therapy in dermatology from experimental state to clinic standard methods. J Environ Pathol Toxicol Oncol 2006;25(1-2):425-39
54. Stender IM, Na R, Fogh H, et al. Photodynamic therapy with 5-aminolaevulinic acid or placebo for recalcitrant foot and hand warts: Randomised double-blind trial. Lancet 2000;355:963-6
55. Fabbrocini G, Di Costanzo MP, Riccardo AM, et al. Photodynamic therapy with topical delta-aminolaevulinic acid for the treatment of plantar warts. J Photochem Photobiol B 2001;61:30-4
56. Sakamoto FH, Torezan L, Anderson RR. Photodynamic therapy for acne vulgaris: A critical review from basics to clinical practice: Part II. Understanding parameters for acne treatment with photodynamic therapy. J Am Acad Dermatol 2010;63:195-211
57. Donnelly RF, McCarron PA, Morrow DI, et al. Photosensitiser delivery for photodynamic therapy. Part 1: Topical carrier platforms. Expert Opin Drug Deliv 2008;5:757-66
58. Fotinos N, Campo MA, Popowycz F, et al. 5-aminolevulinic acid derivatives in photomedicine: basics, application and perspectives. Photochem Photobiol 2006;82:994-1015
59. Peng Q, Berg K, Moan J, et al. 5-aminolevulinic acid-based photodynamic therapy: Principles and experimental research. Photochem Photobiol 1997;65:235-51
60. Van den Akker JT, Iani V, StarWM, et al. Topical application of 5-aminolevulinic acid hexyl ester and 5-aminolevulinic acid to normal nude mouse skin: Differences in protoporphyrin IX fluorescence kinetics and the role of the stratum corneum. Photochem Photobiol 2000;72:681-9
61. Bogaards A, Aalders MC, Zeyl CC, et al. Localization and staging of cervical intraepithelial neoplasia using Double Ratio fluorescence imaging. J Biomed Opt 2002;7:215-20
62. Emtestam L, Nicander I, Stenstrom M, Ollmar S. Electrical impedance of nodular basal cell carcinoma: A pilot study. Dermatology 1998;197:313-16
63. van den Akker JT, Holroyd JA, Vernon DI, et al. Chronic UVB exposure enhances in vitro percutaneous penetration of 5-aminulevulinic acid in hairless mouse skin. Lasers Surg Med 2004;34:141-5
64. van den Akker JTHM, Brown SB. Photodynamic therapy based on 5-aminolevulinic acid: Applications in dermatology. In: Coohill TP, Valenzeno DP, editors. Photobiology for the 21st century. Valdenmar Publishing Co.; Kansas, USA: 2001. p. 165-81
65. Casas A, Batlle A. Aminolevulinic acid derivatives and liposome delivery as strategies for improving 5-aminolevulinic acid-mediated photodynamic therapy. Curr Med Chem 2006;13:1157-68
66. Bugaj A, Juzeniene A, Juzenas P, et al. The effect of skin permeation enhancers on the formation of porphyrins in mouse skin during topical application of the methyl ester of 5-aminolevulinic acid. J Photochem Photobiol B 2006;83:94-7
67. De Rosa FS, Marchetti JM, Thomazini JA, et al. A vehicle for photodynamic therapy of skin cancer: Influence of dimethylsulphoxide on 5-aminolevulinic acid in vitro cutaneous permeation and in vivo protoporphyrin IX accumulation determined by confocal microscopy. J. Control Release 2000;65(3):359-66
68. Turchiello RF, Vena FCB, Maillard PH, et al. Cubic phase gel as drug delivery system for topical application of 5-ALA, its ester derivatives and m-THPC in photodynamic therapy (PDT). J Photochem Photobiol B 2003;70:1-6
69. Merclin N, Bender J, Sparr E, et al. Transdermal delivery from a lipid sponge phase-iontophoretic and passive transport in vitro of 5-aminolevulinic acid and its methyl ester. J Control Release 2004;100:191-8
70. Casas A, Perotti C, Saccoliti M, et al. ALA and ALA hexyl ester in free and liposomal formulations for the photosensitisation of tumour organ cultures. Br J Cancer 2002;86:837-42
71. Fang YP, Wu PC, Tsai YH, Huang YB. Physicochemical and safety evaluation of 5-aminolevulinic acid in novel liposomes as carriers for skin delivery. J Liposome Res 2008;18:31-45
72. Lee WR, Tsai RY, Fang CL, et al. Microdermabrasion as a novel tool to enhance drug delivery via the skin: An animal study. Dermatol Surg 2006;32:1013-22
73. Ma L, Moan J, Peng Q, Iani V. Production of protoporphyrin IX induced by 5-aminolevulinic acid in transplanted human colon adenocarcinoma of nude mice can be increased by ultrasound. Int J Cancer 1998;78:464-9
74. Mizutani K, Watanabe D, Akita Y, et al. Photodynamic therapy using direct-current pulsed iontophoresis for 5-aminolevulinic acid application. Photodermatol Photoimmunol Photomed 2009;25:280-2
75. Krishnan G, Roberts MS, Grice J, et al. Enhanced transdermal delivery of 5-aminolevulinic acid and a dipeptide by iontophoresis. Biopolymers 2011;96:166-71
76. Donnelly RF, Morrow DI, McCarron PA, et al. Microneedle-mediated intradermal delivery of 5-aminolevulinic acid: Potential for enhanced topical photodynamic therapy. J Control Release 2008;129:154-62
77. Donnelly RF, Morrow DI, McCarron PA, et al. Influence of solution viscosity and injection protocol on distribution patterns of jet injectors: Application to photodynamic tumour targeting. J Photochem Photobiol B 2007;89:98-109
78. Barry BW. Novel mechanisms and devices to enable successful transdermal drug delivery. Eur J Pharm Sci 2001;14:101-14
79. Pierre MB, Tedesco AC, Marchetti JM, Bentley MV. Stratum corneum lipids liposomes for the topical delivery of 5-aminolevulinic acid in photodynamic therapy of skin cancer: Preparation and in vitro permeation study. BMC Dermatol 2001;1:5
80. Han I, Jun MS, Kim SK, et al. Expression pattern and intensity of protoporphyrin IX induced by liposomal 5-aminolevulinic acid in rat pilosebaceous unit throughout hair cycle. Arch Dermatol Res 2005;297:210-17
81. Fang YP, Tsai YH, Wu PC, Huang YB. Comparison of 5-aminolevulinic acidencapsulated liposome versus ethosome for skin delivery for photodynamic therapy. Int J Pharm 2008;356:144-52
82. Fang YP, Huang YB, Wu PC, Tsai YH. Topical delivery of 5-aminolevulinic acid-encapsulated ethosomes in a hyperproliferative skin animal model using the CLSM technique to evaluate the penetration behavior. Eur J Pharm Biopharm 2009;73:391-8
83. Oh EK, Jin SE, Kim JK, et al. Retained topical delivery of 5-aminolevulinic acid using cationic ultradeformable liposomes for photodynamic therapy. Eur J Pharm Sci 2011;44:149-57
84. Schmid MH, Korting HC. Liposomes: A drug carrier system for topical treatment in dermatology. Crit Rev Ther Drug Carrier Syst 1994;11:97-118
85. Song YK, Kim CK. Topical delivery of low-molecular-weight heparin with surface-charged flexible liposomes. Biomaterials 2006;27:271-80
86. Song YK, Hyun SY, Kim HT, et al. Transdermal delivery of low molecular weight heparin loaded in flexible liposomes with bioavailability enhancement: Comparison with ethosomes. J Microencapsul 2011;28:151-8
87. Jain S, Jain P, Umamaheshwari RB, Jain NK. Transfersomes-a novel vesicular carrier for enhanced transdermal delivery: Development, characterization, and performance evaluation. Drug Dev Ind Pharm 2003;29:1013-26
88. Burnette RR, Ongpipattanakul B. Characterization of the permselective properties of excised human skin during iontophoresis. J Pharm Sci 1987;76:765-73
89. Manosroi A, Kongkaneramit L, Manosroi J. Stability and transdermal absorption of topical amphotericin B liposome formulations. Int J Pharm 2004;270:279-86
90. Ogiso T, Yamaguchi T, Iwaki M, et al. Effect of positively and negatively charged liposomes on skin permeation of drugs. J. Drug Target 2001;9:49-59
91. Kosobe T, Moriyama E, Tokuoka Y, Kawashima N. Size and surface charge effect of 5-aminolevulinic acid-containing liposomes on photodynamic therapy for cultivated cancer cells. Drug Dev Ind Pharm 2005;31:623-9
92. Cevc G, Schatzlein A, Richardsen H. Ultradeformable lipid vesicles can penetrate skin and other semi-permeable membrane barriers unfragmented. Evidence from double label CLSM experiments and direct size measurement. Biochim Biophys 2002;1564:21-30
93. Casas A, Fukuda H, Di Venosa G, Batlle AM. The influence of the vehicle on the synthesis of porphyrins after topical application of 5-aminolaevulinic acid. Implications in cutaneous photodynamic sensitization. Br J Dermatol 2000;143:564-72
94. Verma DD, Verma S, Blume G, Fahr A. Particle size of liposomes influences dermal delivery of substances into skin. Int J Pharm 2003;258:141-51
95. Cases et al. Unpublished results, cited in: Casas A, Perotti C, Saccoliti M, et al. ALA and ALA hexyl ester in free and liposomal formulations for the photosensitisation of tumour organ cultures. Br J Cancer 2002;86:837-42
96. Fukuda H, Paredes S, Batlle AM. Tumour-localizing properties of porphyrins. In vivo studies using free and liposome encapsulated aminolevulinic acid. Comp Biochem Physiol B 1992;102(2):433-6
97. Casas A, Fukuda H, Di Venosa G, Batlle A. Photosensitization and mechanism of cytotoxicity induced by the use of ALA derivatives in photodynamic therapy. Br J Cancer 2001;85:279-84
98. Di Venosa G, Hermida L, Fukuda H, et al. Comparation of liposomal formulations of ALA Undecanoyl ester for its use in photodynamic therapy. J Photochem Photobiol B 2009;96:152-8
99. Wang XL,Wang HW, Zhang LL, et al. Topical ALA PDT for the treatment of severe acne vulgaris. Photodiagnosis Photodyn Ther 2010;7:33-8
100. Gold MH. The utilization of ALA-PDT and a new photoclearing device for the treatment of severe inflammatory acne vulgaris - results of an initial clinical trial. J Lasers Surg Med 2003;15:46
101. Gold MH, Bradshaw VL, Boring MM, et al. The use of a novel intense pulsed light and heat source and ALA PDT in the treatment of moderate to severe inflammatory acne vulgaris. J Drugs Dermatol 2004;3:15-19
102. Gold MH, Biron JA, Boring M, et al. Treatment of moderate to severe inflammatory acne vulgaris: Photodynamic therapy with 5-aminolevulinic acid and a novel advanced fluorescence technology pulsed light source. J Drugs Dermatol 2007;6:319-22
103. Goldman MP, Boyce S. A single-center study of aminolevulinic acid and 417 nm photodynamic therapy in the treatment of moderate to severe acne vulgaris. J Drugs Dermatol 2003;2:393-6
104. de Leeuw J, Van Der Beek N, Bjerring P, Neumann HA. Photodynamic therapy of acne vulgaris using 5-aminolevulinic acid 0.5% liposomal spray and intense pulsed light in combination with topical keratolytic agents. J Eur Acad Dermatol Venereol 010;24:460-9
105. Wiegell SR, Wulf HC. Photodynamic therapy of acne vulgaris using methylaminolaevulinate: A blinded, randomized, controlled trial. Br J Dermatol 2006;154:969-76
106. An JS, Kim JE, Lee DH, et al. 0.5% Liposome-encapsulated 5-aminolevulinic acid (ALA) photodynamic therapy for acne treatment. J Cosmet Laser Ther 2011;13(1):28-32
107. Yeung CK, Shek SY, Yu CS, et al. Liposome-encapsulated 0.5% 5-aminolevulinic acid with intense pulsed light for the treatment of inflammatory facial acne: A pilot study. Dermatol Surg 2011;37(4):450-9
108. Christiansen K, Bjerring P, Troilius A. 5-ALA for photodynamic photorejuvenation-optimization of treatment regime based on normal skin fluorescence measurements. Lasers Surg Med 2007;39:302-10
109. Bjerring P, Christiansen K, Troilius A, et al. Skin fluorescence controlled photodynamic photorejuvenation (wrinkle reduction). Lasers Surg Med 2009;41(5):327-36
110. Fadel M, Salah M, Samy N, Mona S. Liposomal methylene blue hydrogel for selective photodynamic therapy of acne vulgaris. J Drugs Dermatol 2009;8(11):983-90
111. Lieb LM, Ramachandran C, Egbaria K, Weiner N. Topical delivery enhancement with multilamellar liposomes into pilosebaceous units. I. In vitro evaluation using fluorescent techniques with hamster ear model. J Invest Dermatol 1992;99:108-13
112. Lauer AC. Percutaneous drug delivery to the hair follicle. In: Bronaugh RL, Maibach HI, editors. Percutaneous absorption drugs-cosmetics- mechanismsmethodology. 3rd edition. Marcel Dekker, Inc.; New York, Basel: 1999. p. 427-49
113. Tabbakhian M, Tavakoli N, Jaafari MR, Daneshamouz S. Enhancement of follicular delivery of finasteride by liposomes and niosomes. 1. In vitro permeation and in vivo deposition studies using hamster flank and ear models. Int J Pharm 2006;323:1-10
114. Patel VB, Misra AN, Marfatia YS. Topical liposomal gel of tretinoin for the treatment of acne: Research and clinical implications. Pharm Dev Technol 2000;5:455-64
115. Patel VB, Misra AN, Marfatia YS. Preparation and comparative clinical evaluation of liposomal gel of benzoylperoxide for acne. Drug Dev Ind Pharm 2001;27:863-70
116. Castro GA, Ferreira LA. Novel vesicular and particulate drug delivery systems for topical treatment of acne. Expert Opin Drug Deliv 2008;5:665-79
117. Zane C, Capezzera R, Sala R, et al. Clinical and echographic analysis of photodynamic therapy using methylaminolevulinate as sensitizer in the treatment of photodamaged facial skin. Lasers Surg Med 2007;39(3):203-9
118. Park MY, Sohn S, Lee ES, Kim YC. Photorejuvenation induced by 5-aminolevulinic acid photodynamic therapy in patients with actinic keratosis: A histologic analysis. J Am Acad Dermatol 2010; 2(1):85-95
119. Piccioni A, Fargnoli MC, Schoinas S, et al. Efficacy and tolerability of 5-aminolevulinic acid 0.5% liposomal spray and intense pulsed light in wrinkle reduction of photodamaged skin. J Dermatolog Treat 2011; 22(5):247-53
120. Mitra S, Foster TH. Photophysical parameters, photosensitizer retention and tissue optical properties completely account for the higher photodynamic efficacy of meso-tetra-hydroxyphenyl-chlorin vs Photofrin. Photochem Photobiol 2005;81:849-59
121. Van Geel IP, Oppelaar H, Oussoren YG, et al. Photosensitizing efficacy of MTHPC-PDT compared to photofrin-PDT in the RIF1 mouse tumour and normal skin. Int J Cancer 1995;60:388-94
122. Ris H-B, Altermatt JH, Stewart CM, et al. Photodynamic therapy with m-tetrahydroxyphenylchlorin in vivo: Optimization of the therapeutic index. Int J Cancer 1993;55:245-9
123. Hopper C, Kubler A, Lewis H, et al. mTHPC-mediated photodynamic therapy for early oral squamous cell carcinoma. Int J Cancer 2004;111:138-46
124. Available from: Www.biolitecpharma.com
125. Buchholz J, Kaser-Hotz B, Khan T, et al. Optimizing photodynamic therapy: In vivo pharmacokinetics of liposomal meta-(tetrahydroxyphenyl)chlorin in feline squamous cell carcinoma. Clin Cancer Res 2005;11:7538-44
126. Svensson J, Johansson A, Grafe S, et al. Tumour selectivity at short times following systemic administration of a liposomal temoporfin formulation in a murine tumour model. Photochem Photobiol 2007;83:1211-19
127. Kelbauskas L. Untersuchungen zur Struktur-Eigenschafts-Beziehung selbstassoziierender Photosensibilisatoren mittels zeitaufgeloster Spektroskopie. Friedrich-Schiller University Jena, Jena, Ph.D. Thesis; Germany: 2003
128. Biolitec AG. Jena, Germany, unpublished results cited in: Dragicevic-Curic N, Scheglmann D, et al. Temoporfin-loaded invasomes: Development, characterization and in vitro skin penetration studies. J Control Release 2008;127:59-69
129. Gupta G, Morton CA, Whitehurst C, et al. Photodynamic therapy with mesotetra( hydroxyphenyl)chlorin in the topical treatment of Bowen's disease and basal cell carcinoma. Br J Dermatol 1991;141:385-6
130. Johansson A, Svensson J, Bendsoe N, et al. Fluorescence and absorption assessment of a lipid mTHPC formulation following topical application in a non-melanotic skin tumour model. J Biomed Opt 2007;12:034026
131. Dragicevic-Curic N, Winter S, Stupar M, et al. Temoporfin-loaded liposomal gels: Viscoelastic properties and in vitro skin penetration. Int J Pharm 2009;373(1-2):77-84
132. Dragicevic-Curic N, Winter S, Krajisnik D, et al. Stability evaluation of temoporfin-loaded liposomal gels for topical application. J Liposome Res 2010;20(1):38-48
133. Dragicevic-Curic N, Grafe S, Albrecht V, Fahr A. Topical application of temoporfin-loaded invasomes for photodynamic therapy of subcutaneously implanted tumours in mice: A pilot study. J Photochem Photobiol B 2008;91(1):41-50
134. Dragicevic-Curic N, Grafe S, Gitter B, Fahr A. Efficacy of temoporfin-loaded invasomes in the photodynamic therapy in human epidermoid and colorectal tumour cell lines. J Photochem Photobiol B 2010;101(3):238-50
135. Dragicevic-Curic N, Scheglmann D, Albrecht V, Fahr A. Development of liposomes containing ethanol for skin delivery of temoporfin: Characterization and in vitro penetration studies. Colloids Surf B Biointerfaces 2009;74(1):114-22
136. Dragicevic-Curic N, Grafe S, Gitter B, et al. Surface charged temoporfin-loaded flexible vesicles: In vitro skin penetration studies and stability. Int J Pharm 2010;Jan15384(1-2):100-8
137. Bendsoe N, Persson L, Johansson A, et al. Fluorescence monitoring of a topically applied liposomal Temoporfin formulation and photodynamic therapy of nonpigmented skin malignancies. J Environ Pathol Toxicol Oncol 2007;26:117-26
138. Rhodes LE. Essential fatty acids. In: Loden M, Maibach HI, editors. Dry skin and moisturizers. Chemistry and Function; Boca Raton, London, New York: 2000. p. 311-25
139. Fluhr JW, Berardesca E. Effects of moisturizers and keratolytic agents in psoriasis. In: Loden M, Maibach HI, editors. Dry skin and moisturizers. Chemistry and Function; Boca Raton, London, New York: 2000. p. 167-72
140. McCarron PA, Donnelly RF, Andrews GP, Woolfson AD. Stability of 5-aminolevulinic acid in novel non-aqueous gel and patch-type systems intended for topical application. J Pharm Sci 2005;94:1756-71
141. Thoma K, Jocham UE. Liposome dermatics: Assessment of long-term stability. In: Braun-Falco O, Korting HC, Maibach HI, editors. Liposome Dermatics. Springer-Verlag; Berlin: 1992. p. 150-66